Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesInfectious Agent Antigen DetectionCPT cpt-87426-sars-cov-2-antigen-immunoassay-blood
    Ask Trek AI about this page

    CPT 87426: SARS–CoV–2 Antigen Immunoassay, Blood

    Commercial payers pay $39 on average nationally for this procedure.

    CPT code 87426 describes a laboratory immunoassay performed to qualitatively or semiquantitatively detect antigens of severe acute respiratory syndrome coronavirus (such as SARS–CoV–2) in a patient blood specimen, representing a diagnostic infectious agent antigen test typically performed by clinical laboratory personnel; service type: laboratory diagnostic test; typical site of service: clinical laboratory or hospital laboratory.

    For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.

    Customize your policy alerts

    Sign up for cpt 87426 policy alerts

    Get alerted when payer policies referencing 87426 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial rates for CPT 87426 center on BUCA’s mean of $38.70 as the average commercial benchmark, with individual payer medians and means showing meaningful variation. Blue Cross Blue Shield’s interquartile spread (P75–P25) is $13.00, Cigna’s spread is $24.40, Aetna’s spread is $11.10, and UnitedHealth Group’s spread is $22.60, indicating that Blue Cross Blue Shield and Aetna have the tightest middle-range dispersions while Cigna and UnitedHealth Group exhibit wider volatility in the middle 50% of rates.

    Looking at extremes and central tendency, Aetna and UnitedHealth Group show the largest upper-end maximums at $114.80 and $140.00 respectively, while Cigna and Aetna include the lowest observed minimums at $5.20 and $9.10. BUCA’s mean of $38.70 sits near the midpoint of payer means, underscoring that average commercial reimbursement falls in the high $30s despite notable payer-specific spread differences.

    Table of contents

    Progress1 / 8

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 58-year-old patient presents to a primary care clinic with fever, cough, and shortness of breath. The clinician documents a suspected COVID-19 infection and orders laboratory testing. A phlebotomy technician collects a blood specimen which is routed to the clinical laboratory. A medical laboratory scientist or lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the specimen for SARS–CoV–2 antigens, supporting diagnosis of acute infection. Typical workflow: clinician order placed; specimen collection and labeling; transport to Clinical Medical Laboratory; accessioning and processing; immunoassay performed using validated SARS–CoV–2 antigen kit; result validated by laboratorian; final report released to ordering Family Medicine or Internal Medicine provider; electronic health record updated and care plan adjusted (isolation, additional testing such as nucleic acid amplification testing, or treatment) based on results and clinical context. Typical site of service: outpatient clinic laboratory, hospital laboratory, or independent clinical laboratory. Typical patient scenario includes symptomatic patients with ICD-10 codes such as U07.1 (confirmed COVID-19), R05 (cough), screening encounters Z11.52, known exposure Z20.822, or COVID-19 pneumonia J12.82 when antigen testing is used as part of diagnostic evaluation or screening.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    95Modifier 95 indicates that a service was provided via synchronous, real‑time audio‑video telehealth rather than in‑person. Per CMS, AAPC and professional associations, append modifier 95 to claim…- Use modifier 95 to indicate a service was furnished via synchronous, real‑time audiovisual telehealth (a live audio‑video conference between patient and provider) rather than in‑person. - Pair…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    291U00000X
    207Q00000X
    207R00000X
    163WA0400X
    2084N0008X
    367500000X
    2251E1200X
    204R00000X

    Related Payer Policy Updates

    Specialty: Infectious Disease1 / 3

    10 rows

    PolicyPayerEffective Date
    Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    HIV/AIDS Pharmacologic Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    Long-Acting Injectable Antiretroviral Agents for HIVColorado Rocky Mountain Health Plans2026-10-01
    B-Hemolytic Streptococcus TestingOscar Health2026-10-01
    Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance AssaysOscar Health2026-10-01
    Hepatitis Testing (A, B, C, D) Coverage CriteriaOscar Health2026-10-01
    Pathogen Panel TestingOscar Health2026-10-01
    Lyme Disease Testing Coverage CriteriaOscar Health2026-10-01
    Diagnostic Testing of Common Sexually Transmitted InfectionsOscar Health2026-10-01
    Testing for Diagnosis of Active or Latent TuberculosisOscar Health2026-10-01

    Related Codes

    CPT-87260-ADENOVIRUS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87260: Adenovirus Antigen Detection by Immunofluorescence

    CPT-87265-BORDETELLA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87265: Bordetella Antigen Detection by Immunofluorescence

    CPT-87267-ENTEROVIRUS-DFA-ANTIGEN-DETECTION

    CPT 87267: Enterovirus Antigen Detection by DFA

    CPT-87269-GIARDIA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87269: Giardia Antigen Detection by Immunofluorescence

    CPT-87270-CHLAMYDIA-TRACHOMATIS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87270: Chlamydia trachomatis Antigen Detection by Immunofluorescence

    CPT-87271-CMV-DFA-ANTIGEN-DETECTION

    CPT 87271: CMV Antigen Detection by Direct Fluorescent Antibody

    CPT-87272-CRYPTOSPORIDIUM-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87272: Cryptosporidium Antigen Immunofluorescent Test

    CPT-87273-HSV-2-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87273: HSV-2 Antigen Detection by Immunofluorescence

    CPT-87274-HSV-1-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87274: HSV-1 Antigen Detection by Immunofluorescence

    CPT-87275-INFLUENZA-B-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87275: Influenza B Antigen Detection by Immunofluorescence

    Showing 1–10 of 167

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    87635Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2Molecular NAAT performed when higher sensitivity is needed or to confirm antigen results
    87811Infectious agent antigen detection by immunoassay with direct optical observation; SARS-CoV-2Alternative antigen detection methodology; may represent point-of-care or lab-based antigen testing
    86769Antibody detection, SARS-CoV-2Serologic testing for prior infection or immune response; not used for acute antigen detection but often ordered in different clinical contexts
    86328Immunoassay for infectious agent antibody, qualitative or semiquantitative; SARS-CoV-2Another serologic immunoassay code for antibody testing; complementary to antigen testing in clinical workflows